BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  05/20 04:00:01 pm EDT
252.30 USD   +0.46%
05/19BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partnership agreement to explore new ways to advance biologic drug delivery
AQ
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales Outlook
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton, Dickinson and Company and Pfizer Inc Collaborates to Improve Global Hospital Antimicrobial Stewardship Practices

01/11/2022 | 06:50am EDT

Becton, Dickinson and Company announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better understand the role of diagnostics in advancing antimicrobial stewardship practices around the world. Building on ongoing efforts to advance the role of diagnostics in tackling the challenge of antimicrobial resistance (AMR), this collaboration will survey existing diagnostic practices to highlight both benefits and gaps in diagnostic testing in AMR stewardship to improve and further advocate for patient care, clinical practice and health care economics. AMR occurs when bacteria, viruses, fungi or parasites change over time and no longer respond to medicines. These changes make infections harder to treat and increase the risk of disease transmission, severe illness and death. As the organisms that cause infections become increasingly drug resistant, even common medical procedures — including surgery, childbirth and chemotherapy — can become increasingly life-threatening.ii A continued rise in AMR could take 10 million lives globally each year by 2050 – more than currently die from cancer. The important role diagnostics can play as a tool to improve appropriate use of antibiotics is recognized by policymakers and advocates. AMR Review — an organization commissioned by the U.K. prime minister and chaired by Lord Jim O'Neill — includes promotion of "new rapid diagnostics to cut unnecessary use of antibiotics" as one of its 10 primary recommendations.iv However, progress in implementing the AMR Review's recommendations remains slow and diagnostics remain an under-utilized resource for optimizing antimicrobial (antibacterial, antifungal and antiviral) treatments and supporting antimicrobial stewardship efforts.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
BECTON, DICKINSON AND COMPANY 0.46% 252.3 Delayed Quote.2.66%
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
All news about BECTON, DICKINSON AND COMPANY
05/19BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partne..
AQ
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales..
MT
05/12BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Pl..
PR
05/12Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Dise..
CI
05/11TRANSCRIPT : Becton, Dickinson and Company Presents at Bank of America 2022 Healthcare Con..
CI
05/11Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New C..
PR
05/11Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collect..
CI
05/10INSIDER SELL : Becton Dickinson
MT
05/06Piper Sandler Adjusts Price Target on Becton Dickinson and Co. to $255 From $265, Maint..
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 743 M - -
Net income 2022 1 746 M - -
Net Debt 2022 13 463 M - -
P/E ratio 2022 35,1x
Yield 2022 1,51%
Capitalization 71 922 M 71 922 M -
EV / Sales 2022 4,56x
EV / Sales 2023 4,32x
Nbr of Employees 75 000
Free-Float 77,6%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 252,30 $
Average target price 283,08 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY2.66%71 922
ABBOTT LABORATORIES-19.54%198 277
MEDTRONIC PLC-0.89%137 548
HOYA CORPORATION-22.41%37 902
BAXTER INTERNATIONAL INC.-14.69%36 873
DEXCOM, INC.-40.18%31 521